A new approach to the overcoming resistance to hormone therapy of breast cancer


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Although hormonal therapy is the primary treatment of patients with hormone-dependent breast cancer (BC), the achievement of response to treatment is not possible in all cases. This refers to the development of primary (de novo) or secondary (acquired) resistance to previous hormone therapy, and is well-founded reason for discontinuation of hormone therapy and the initiation of chemotherapy in some cases. Current 2012 was marked by advances in targeted therapy for metastatic breast cancer that is resistant to standard drug treatment programs. The use of innovative anti-mTOR-drug everolimus (an inhibitor of the proliferative signaling) in combination with exemestane (a steroidal aromatase inhibitor) allows not only to overcome the resistance to previous hormone therapy, but to preserve the quality of life of BC patients, thereby extending their working life.

Full Text

Restricted Access

References

  1. Инструкция по медицинскому применению препарата Афинитор® ЛСР 002260/10 от 130612.2. Распоряжение Правительства РФ №2199р от 7 декабря 2011 г. «Об утверждении перечня жизненно необходимых и важнейших лекарственных препаратов на 2012 год», http://wYiw.minzdravsoc.ru/docs/government/72
  2. Семиглазов В.Ф. Стратегические и практические подходы к решению проблемы рака молочной железы// Вопр. онкол. 2012. Т. 58. № 2. С. 148-52.
  3. Семиглазов В.Ф., Манихас А.Г., Семиглазова Т.Ю., Бессонов А.А., Семиглазов В.В. Неоадъювантная системная терапия рака молочной железы// Руководство для врачей. СПб., 2012. 112 с.
  4. Bachelot T., Bourgier C., Cropet C., et al. Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2 - negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study. J Clin Oncol 2012;30:2718-24.
  5. Baselga J., Campone M., Piccart M., et al. Everolimus in Postmenopausal Hormone-Receptor - Positive Advanced Breast Cancer. N ENGL J MED 2012;366(6):520.
  6. Baselga J., Semiglazov V., van Dam., et al. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. J Clin Oncol 2009;27:2630-37.
  7. Baum M., Buzdar A., Cuzick J., et al. ATAC (Arimidex, Tamoxifen Alone or in Combination) Trialists' Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer 2003;98:1802-10.
  8. Beck J., Rugo H., Howard A., et al. BOLERO-2: Health-related quality-of-life in metastatic breast cancer patients treated with everolimus and exemestane versus exemestane. J Clin Oncol 2012;30 (Suppl.):abstr.539.
  9. Boulay A., Rudloff J., Ye J., et al. Dual inhibition of mTOR and estrogen receptor signaling in vitro induces cell death in models of breast cancer. Clin Cancer Res 2005;11:5319-28.
  10. Boyle W.J., Simonet W.S., Lacey D.L. Osteoclast differentiation and activation. Nature 2003;423:337-42.
  11. Burstein H.J. Novel agents and future directions for refractory breast cancer. Semin Oncol 2011;38(Suppl. 2):17-24.
  12. Coleman R.E., Banks L.M., Girgis S.I., et al. Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study. Lancet Oncol 2007;8:119-27.
  13. Coombes R.C., Hall E., Gibson L.J., et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004;350:1081-92.
  14. Crivellari D., Sun Z., Coates A.S., et al. Letrozole compared with tamoxifen for elderly patients with endocrine-responsive early breast cancer: the BIG 1-98 trial. J Clin Oncol 2008; 26:1972-79.
  15. Efeyan A., Sabatini D.M. mTOR and cancer: many loops in one pathway. Curr Opin Cell Biol 2010;22:169-76.
  16. Glantschnig H., Fisher J., Wesolowski G., et al. M-CSF, TNFalpha and RANK ligand promote osteoclast survival by signaling through mTOR/S6 kinase. Cell Death Differ 2003;10:1165-77.
  17. Gnant M., Baselga J., Rugo H., et al. Effects of everolimus (EVE) on disease progression in bone and bone markers (BM) in patients (pts) with bone metastases (mets). J Clin Oncol 2012;30:abstr.512.
  18. Goss P.E., Ingle J.N., Martino S., et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst 2005;97:1262-71.
  19. Howell A. ATAC trial update. Lancet 2005;365:1225-26.
  20. Jakesz R., Jonat W., Gnant M., et al. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 2005;366:455-62.
  21. Johnston S.R. Clinical efforts to combine endocrine agents with targeted therapies against epidermal growth factor receptor/ human epidermal growth factor receptor 2 and mammalian target of rapamycin. in breast cancer. Clin Cancer Res 2006;12:1061-68.
  22. Johnston S.R. New strategies in estrogen receptor-positive breast cancer. Clin Cancer Res 2010;16:1979-87.
  23. Kearns A.E., Khosla S., Kostenuik P.J. Receptor activator of nuclear factor B ligand and osteoprotegerin regulation of bone remodeling in health and disease. Endocr Rev 2008; 29:155-92.
  24. Kneissel M., Luong-Nguyen N.-H., Baptist M., et al. Everolimus suppresses cancellous bone loss, bone resorption, and cathepsin K expression by osteoclasts. Bone 2004;35:1144-56.
  25. Schiff R., Massarweh S., Shou J., et al. Crosstalk between estrogen receptor and growth factor pathways as a molecular target for overcoming endocrine resistance. Clin Cancer Res 2004;10:331-36.
  26. Wright H.L., McCarthy H.S., Middleton J., et al. RANK, RANKL and osteoprotegerin in bone biology and disease. Curr Rev Musculoskelet Med 2009;2:56-64.
  27. Yamnik R., Holz K. mTOR/S6K and MAPK/RSK signaling pathways coordinately regulate estrogen receptor alphaserine 167 phosphorylation. FEBS Lett 2010;584:124-28.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2012 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies